 13. Subjects with any medical condition which is likely to interfere with the evaluation of the study drugs andor the satisfactory conduct of the clinical trial according to the investigators judgment e.g. congenital or acquired bleeding disorders other than congenital fibrinogen deficiency, planned surgery needing blood transfusion 